Related Experiment Video

Updated: Jun 24, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

Targeting SRC and epidermal growth factor receptor in colorectal cancer: rationale and progress into the clinic

Scott Kopetz1

  • 1Department of Gastrointestinal Medical Oncology, University of Texas M. D. Anderson Cancer Center, Houston, TX.

Gastrointestinal Cancer Research : GCR
|April 11, 2009
PubMed

Insights

Src kinase plays a key role in colorectal cancer progression and metastasis. Inhibiting Src shows promise for combination therapies, enhancing treatments with EGFR antibodies and chemotherapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Src is a non-receptor protein tyrosine kinase crucial for colorectal cancer (CRC) cell functions.
  • Src activation is an early epigenetic event in CRC, increasing with tumor metastasis.
  • Src signaling is linked to epidermal growth factor receptor (EGFR) pathways.

Purpose of the Study:

  • To review the role of Src in colorectal cancer.
  • To explore the therapeutic potential of Src inhibitors in combination regimens.
  • To discuss current Src inhibitors in clinical trials.

Main Methods:

  • Literature review of Src's role in colorectal cancer.
  • Analysis of Src's involvement in EGFR transactivation.
  • Evaluation of synergistic effects of Src inhibitors with other therapies.

Main Results:

  • Src kinase activity influences CRC proliferation, angiogenesis, migration, invasion, and apoptosis.
  • Src uniquely activates EGFR without ligand, showing synergy with EGFR monoclonal antibodies.
  • Src inhibition demonstrates in vivo synergy with platinum chemotherapeutics.

Conclusions:

  • Src is a significant therapeutic target in colorectal cancer.
  • Combination therapies involving Src inhibitors offer enhanced efficacy.
  • Src inhibitors hold potential for improving colorectal cancer treatment strategies.

More Related Videos

An Immunofluorescent Method for Characterization of Barrett’s Esophagus Cells08:54

An Immunofluorescent Method for Characterization of Barrett’s Esophagus Cells

Published on: July 20, 2014

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization03:08

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization

Published on: October 3, 2025

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...